Application No. 09/944,564 Page 1

Inventor: Nida Abdul-Ghani Nassief

CLAIMS

- 1-24. (Canceled)
- 25. (New) A pharmaceutical composition consisting essentially of glycophosphopeptical for oral administration for the treatment of allergy and asthma in dosage and duration which is effective to:
 - i- Switch-off the airway eosinophilic inflammation.
 - ii- Reduce mucus secretion.
 - iii- Reduce symptom scores significantly.
 - iv- Restore airways patency as measured by Pulmonary Function Test.
- 26. (New) A pharmaceutical composition of claim 25, to induce a clinical remission and long-term therapeutic effect in a chronically ill patient.
- 27. (New) A method of treatment of allergy and asthma patients in need of multiple drugs daily, comprising of administering the pharmaceutical composition of claim 25 for a short course of 1-14 days to induce a remission of 3-12 months.
- 28. (New) A pharmaceutical composition for the treatment of allergy and asthma consisting essentially of the herbal seeds of Nigella sativa to act as a vaccine that is almost identical to Purified Protein Derivative from Bacillus Calmette Guréin:
 - i- Switch-off the airway eosinophilic inflammation.
 - ii- Reduce mucus secretion.
 - iii- Reduce symptom scores significantly.
 - iv- Restore airways patency as measured by Pulmonary Function Test.
- 29. (New) A pharmaceutical composition vaccine of claim 28, to induce a clinical remission and long-term therapeutic effect in a chronically ill patient suffering from asthma and allergy.
- 30. (New) A method of treatment of allergy and asthma patients in need of multiple drugs daily, comprising of administering the pharmaceutical composition of claim 28 for a short course of 1-14 days to induce a remission of 3-12 months.
- 31. (New) A pharmaceutical composition vaccine from Nigella sativa, to induce a clinical remission and long-term therapeutic effect in patients with Crohn's disease.
- 32. (New) A method of treatment of Crohn's disease, comprising of administering the pharmaceutical composition vaccine from Nigella sativa for a short course of 1-14 days to induce symptomatic remission.
- (New) A pharmaceutical composition vaccine from Nigella sativa, to induce a clinical remission and long-term therapeutic effect in patients with influenza and common cold.

 (New) A method of treatment of influenza and common cold, comprising of administering the pharmaceutical composition vaccine from Nigella sativa for a short course of 1-14 days to induce symptomatic remission.